TY - GEN AU - Cancelo-Hidalgo,M.J. AU - Coronado-Martín,P.J. AU - Herrero-Conde,M. AU - Martínez-Aspas,A. AU - Martínez-Maestre,M.Á. AU - Perelló-Capo,J. AU - Sánchez-Borrego,R. KW - Climateric KW - Elinzanetant KW - KNDy neuron KW - Menopause KW - Mood disorders KW - Neurokinin B KW - Neurokinin receptor-targeted therapy KW - Receptor NK1 antagonist KW - Receptor NK3 antagonist KW - Sleep disorders KW - Sleep Wake Disorders KW - Substance P KW - Vasomotor symptoms T1 - Vasomotor symptoms and sleep and mood disturbances in the climacteric: new perspectives with neurokinin receptor-targeted therapies TI - Síntomas vasomotores y alteraciones del sueño y anímicas en el climaterio: nuevas perspectivas con las terapias dirigidas a los receptores de neuroquininas LA - spa PY - 2026/04/01/ T2 - Clinica e Investigacion en Ginecologia y Obstetricia SN - 1578-9349 VL - 53 IS - 2 PB - Elsevier Espana S.L.U AB - The transition to menopause is a process of variable duration associated with various endocrine, physical, and psychological changes and irregular menstrual cycles. During this period, up to 85% of women experience climacteric symptoms, of which vasomotor symptoms (VMS) and sleep and mood disturbances (depression or anxiety) are among the most frequent and have the greatest impact on women's quality of life. Although VMS can impact sleep quality and mood, these symptoms can occur independently. This review addresses the epidemiology, relevance, and etiopathogenesis of VMS, sleep and mood disorders, and the current treatments (hormonal and other pharmacological and non-pharmacological options) available to relieve these cardinal climacteric symptoms. Advances in the understanding of the etiopathogenesis of these symptoms and, in particular, the role of neurotransmitters neurokinin B (NKB)—involved in several reproductive processes—and substance P—related to sleep and mood regulation—, and their receptors (neurokinin 3 receptor [NK-3R] and neurokinin 1 receptor [NK-1R]), have prompted the development of neurokinin receptor-targeted therapies for the treatment of menopause. These include fezolinetant (NK-3R antagonist) and elinzanetant (NK-3R and NK-1R antagonist). We update the available evidence on the improvement of these climacteric symptoms with neurokinin receptor-targeted therapies. DO - 10.1016/J.GINE.2026.101089 UR - https://portalcientifico.uah.es/documentos/69a3b17bc355ec16584b68d1 DP - Dialnet - Portal de la Investigación ER -